Intravascular optical coherence tomography (OCT) proved safe, feasible, and capable of providing high-quality images in patients undergoing protected carotid artery stenting, results of a small clinical study showed.
The term“intracranial aneurysm” is a purely descriptive term meaning a widening of the lumen of a segment of an intracranial artery. It is also a collective term for a rather large group of different diseases affecting the extra- and/or intradural portions of intracranial arteries in a segmental, focal or multifocal pattern. Since the currently available non-invasive and invasive neuroimaging modalities, i.e. cross-sectional native and contrast-enhanced CT and MRI, CT- and MR-angiography, or DSA, almost exclusively depict the lumen of intracranial aneurysms but not, or insufficiently, their other components (i.e. the wall and the perianeurysmal space), neurointerventionists tend to base their research and collaboration on developing treatment tools, their clinical decisions, therapeutic actions and follow-up evaluations on the easily visualised lumen. Accordingly, the majority of the currently used classification systems and treatment guidelines for such aneurysms are lumen-oriented and therefore incomplete. This misleads one to view intracranial aneurysms as simple, more or less focal expansions or ectasias of the parent artery lumen induced by haemodynamic forces, such as flow, shear stress and turbulence, instead of considering them to be pathomorphological expressions of distinct pathobiological processes leading to degradation, activation, overproduction or proliferation of a distinct, genetically or otherwise vulnerable segment of the wall of an intracranial artery within a specific local perianeurysmal environment.
Blockade Medical™ announced today that it has received CE Mark (Conformité Européenne) for its Barricade Coil System™. The Barricade Coil System is designed to remove or endovascularly occlude blood flow in vascular abnormalities of the neurovascular and peripheral vessels. The CE Mark allows the Company to market the Barricade Coil System in the European Union and other countries that recognize the CE Mark for commercial distribution purposes The Barricade Coil System provides the neurovascular specialist with a complete coil embolization line that can occlude complex neurovascular aneurysms and other vascular abnormalities.
Our ability to see inside the arteries of vascular disease patients in stunning high resolution before and during stenting procedures can offer a wealth of valuable information. A new study of optical coherence tomography (OCT) confirms the safety and feasibility of this imaging technique in the carotid arteries. However, because of cost issues, OCT still has a long road to travel to become widely utilized.
According to a new report by iData Research (http://www.idataresearch.net), the leading global authority in medical device market research, the European neurological device market was valued at over €600 million in 2011. The market has shown strong growth over the past few years and is expected to reach nearly €850 million by 2018. Market expansion has been fueled by the continued acceptance of endovascular techniques and neuromodulation devices, increases in the aging population, as well as technological advancements.
Penumbra, Inc., announces the launch of an educational website QuEST2StopStroke.com, designed to empower the public with the knowledge they need to help stop stroke. The website asks visitors to “Join the Quest” and learn where to find their closest advanced stroke center that offers lifesaving inside-the-artery clot removal. The website also provides educational information about ischemic stroke and common treatment methods, as well as testimonials from patients whose lives were saved by the Penumbra System®, an innovative clot-removal technology that uses suction and acts as a tiny “vacuum cleaner” to remove blood clots from the brain.
A study from Japan, published in late June in the New England Journal of Medicine, provides information on the natural history of unruptured cerebral aneurysms from over 6,600 aneurysms.
The FDA has issued a warning notice about a potential problem with Covidien subsidiary eV3′s Onyx Liquid Embolic System. Rather than recalling the device it seems issuing a warning and modifying instructions for use to raise awareness of the risk of the catheter device becoming entrapped in brain tissues is deemed adequate
Stroke patients treated who received hormonal treatment, combined with rehabilitation, performed better on functioning and reasoning tests than patients who received rehabilitative therapy alone, a new clinical study from Italy shows. The results of this study were presented at the Endocrine Society s 94th Annual Meeting in Houston, USA.
NeuroSigma announced that it received ISO 13485: 2003 certification, indicating that it operates a Quality Management System for the design, manufacturing and distribution of its external Trigeminal Nerve Stimulation (eTNS) system for the treatment of neurological and neuropsychiatric disorders. This certification is an important first step in a two-step process towards CE mark approval in the European Union.
Botox could soon become a NHS treatment option to prevent headaches in some adults who experience chronic migraine. The National Institute for Health and Clinical Excellence (NICE) published its final draftguidance on Friday 11 May which recommends the injections for the condition.
The new guidance strengthens a recommendation from the 2009 version and updates were based on studies published between 2006 and May 1, 2010. It includes 22 new and nine revised recommendations.
Warfarin was no better than aspirin in reducing the composite of stroke of any kind or death in heart failure patients in sinus rhythm, but had an advantage for reducing ischemic stroke, a randomized trial found.
Despite popular belief, gum disease has not been proven to cause atherosclerotic heart disease or stroke, and treating gum disease has not been proven to prevent heart disease or stroke, according to a new scientific statement published in Circulation, an American Heart Association journal.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos